Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00264186
Status:
COMPLETED
Last Update Posted:
2008-05-22
First Post:
2005-12-09
Brief Title:
Recombinant Human Superoxide Dismutase rhSOD and Vascular Reactivity
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Impact of rhCuZn SOD on Inflammation-Induced Impairment of Vascular Reactivity
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Inflammation is characterised by an increased risk for cardiovascular events Dysfunction of the vascular endothelium caused by oxidative stress might provide a mechanistic link In acute and chronic inflammation oxidative stress occurs when the production of reactive oxygen species ROS including superoxide anions O2- exceeds the capacity of the endogenous antioxidant defense systems resulting in ROS-mediated damage Recombinant human superoxide dismutase rhSOD has shown potent antioxidant properties in in-vitro and animal studies and has been tested in phase I clinical trials in humans rhSOD could offer a therapeutic option for vascular dysfunction in diseases associated with increased oxidative stress The investigators therefore want to test if the hyporesponsiveness to vasoactive drugs norepinephrine acetylcholine and glyceroltrinitrate during acute inflammation by low-dose lipopolysaccharide LPS is due to the increased production of superoxide anions which could be scavanged by the radical scavenger rhSOD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None